高密度脂蛋白-膽固醇（HDL-C）低于正常水平是誘發(fā)心血管疾病的因素之一，升高較低水平的HDL-C能夠降低患心血管疾病的風(fēng)險(xiǎn)。一些代謝疾病，如胰島素耐受、高三酰甘油血癥都會(huì)增強(qiáng)膽固醇酯轉(zhuǎn)移蛋白的活性，高活性的膽固醇酯轉(zhuǎn)移蛋白可誘發(fā)動(dòng)脈粥樣硬化和增加患心血管疾病的風(fēng)險(xiǎn)。因此，抑制膽固醇酯轉(zhuǎn)移蛋白是治療動(dòng)脈粥樣硬化癥的新靶點(diǎn)。Aanncetrapib是一小分子 唑烷酮類選擇性膽固醇酯轉(zhuǎn)移蛋白抑制劑，能很好地作用于低密度脂蛋白-膽固醇（LDL-C）和HDL-C，安全有效地調(diào)節(jié)冠狀動(dòng)脈心臟病患者以及冠狀動(dòng)脈心臟病高危患者的脂質(zhì)水平。

Subnormal plasma levels of high-density lipoprotein cholesterol (HDL-C) constitute a major cardiovascular risk factor. Raising low HDL-C levels may therefore reduce the residual cardiovascular risk that frequently presents in dyslipidaemic subjects. The activity of Cholesteryl ester transfer protein (CETP) is levated in the dyslipidaemias of metabolic disease involving insulin resistance, hypertriglyceridaemia, and leads premature atherosclerosis and high cardiovascular risk. CETP inhibition therefore is regarded as a potential target for elevation of HDL-C and reduction in atherosclerosis. Treatment with Anacetrapib that a CETP inhibitor had strong effects on low-density lipoprotein (LDL) and HDL-C, according to recent study. Further studies of Anacetrapib, specifically in long-term, large-scale outcome trials, will provide essential information on its safety and ef?cacy in reducing residual cardiovascular risk.